Entire sample (n = 8157)
|
Increase in Cl−, mmol L− 1*
|
Q1: ≤1 mmol L− 1
|
1
|
(0.802)
|
Q2: 1–3 mmol L− 1
|
1.22 (0.65, 2.28)
|
0.542
|
Q3: 3–6 mmol L− 1
|
0.86 (0.46, 1.62)
|
0.642
|
Q4: > 6 mmol L− 1
|
1.00 (0.53, 1.89)
|
0.992
|
Interaction of Cl− increase with eGFRa
|
Increase in Cl−: Q1 * eGFR: ≥ 90
|
1
|
(0.960)
|
Increase in Cl−: Q2 * eGFR: 60–89
|
0.62 (0.23, 1.67)
|
0.348
|
Increase in Cl−: Q2 * eGFR: 30–60
|
1.01 (0.31, 3.30)
|
0.990
|
Increase in Cl−: Q2 * eGFR: < 30
|
0.00 (0.00)
|
0.996
|
Increase in Cl−: Q3 * eGFR: 60–89
|
1.14 (0.46, 2.79)
|
0.780
|
Increase in Cl−: Q3 * eGFR: 30–60
|
1.44 (0.48, 4.37)
|
0.518
|
Increase in Cl−: Q3 * eGFR: < 30
|
2.52 (0.38, 16.95)
|
0.342
|
Increase in Cl−: Q4 * eGFR: 60–89
|
0.96 (0.38, 2.44)
|
0.937
|
Increase in Cl−: Q4 * eGFR: 30–60
|
1.52 (0.50, 4.62)
|
0.460
|
Increase in Cl−: Q4 * eGFR: < 30
|
2.53 (0.38, 17.01)
|
0.341
|